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Sir,
Two of the statements within the abstract of this paper (Ahmed
et al, 2009) have been seized upon (and misinterpreted) in a recent
press release and subsequent press articles. The misinterpretations
have arisen from an unfortunate lack of precision in the wording of
the abstract. As there has been so much press coverage, and as
patient recruitment to further HIFU studies is occurring now on
the site bearing the press release, I feel it is important that the
ambiguities of the abstract are discussed and corrected.
The two abstract claims (with ambiguous wording in bold) are
these:
1. ‘Overall there was no evidence of disease after one HIFU
session in 92.4% (159 of 172) of patients’ – the time after
operation of this measurement is not stated. Press release and
press articles uniformly assume that it was at 12 months.
2. ‘Potency was maintained in 70% by 12 months’ – the patient
population on which this was measured is not stated in the
abstract. Press release and press articles assume that it was the
whole group (and wrongly deduce that only 30–40% of the
measured group were impotent at 12 months).
First, ‘92% no evidence of disease etc’: The statement appears as a
summary of the results. The data for this measurement point are
not explicitly presented in the abstract or paper. This makes it
impossible to be certain of the time of measurement.
From the size of the patient group (172 patients, i.e., all patients)
this would appear to be a very early measurement point (shortly
after the operation). This can be inferred from the data in Table 3
(p.22) and the Kaplan–Meier curves (p 23). These show data for
fewer patients at each successive milestone (lost to follow-up, died
or not yet reached the milestone), with data for only 155 patients at
3 months. It is not evident which test is used for ‘evidence of
disease’ at this early measuring point – possibly PSAp0.5ngml
1
(units of mgml
1 appear in the abstract but nowhere else). It is
particularly unfortunate that early data have been highlighted
without it being noted that it is early data. In addition, the use of
such early data as an ‘overall’ summary of performance does not
seem to be appropriate, particularly as the later data (78% of 83
patients show no evidence of disease at 12 months) are also given
in the abstract, and thus seem to be contradicted by the summary.
Second, ‘70% maintain potency etc’: It is slightly difficult to follow
from the paper how many were in the group assessed, possibly due
to a typo. However, the statement appears to be based on results
from 34 patients at 12 months, of whom 16 were potent at 12 months
whilst 24 out of 51 patients were potent before the procedure. Thus,
16 out of 24 gives 66.7% maintaining potency (p 21). The text of the
paper mentions that potency questionnaires were available for 49
patients at 12 months (p 20); only 34 (or is it 51?) appear in the data
s e ta n a l y s e da t1 2m o n t h s( p2 1 ) .
The rates of return of questionnaire between the groups ‘potent
before procedure’ and ‘impotent before procedure’ are not
addressed but could potentially introduce some bias. Even if data
are available for every patient who has reached the 12-month
milestone, the lack of information on Viagra use (before and after)
would make it impossible to assess how much impotency has been
caused by the procedure. In all, it appears very unsafe to
extrapolate the potency results from this small sample to the
whole test population. The authors do not do so; the error of the
press in doing so might have been avoided if the authors had
specified the sample size in the abstract and presented more
comment on the reliability of these specific data.
Both these claims and their subsequent misrepresentations in
the press have been used to make invalid comparisons with other
more conventional treatments. Patients volunteering for HIFU
should do so in the light of full and correct information. I would
urge the authors to make public the necessary clarifications.
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